Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Jan;20(1):167-8.
doi: 10.1038/sj.leu.2404012.

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

A Tchirkov, J-L Couderc, B Périssel, C Goumy, A Regnier, N Uhrhammer, P Verrelle, M Berger
Case Reports

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

A Tchirkov et al. Leukemia. 2006 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) RT-PCR for BCR-ABL mRNA with e1a2 primers (lanes 1–4) and e8a2 primers (lanes 5–7). Patient’s bone marrow (lanes 1 and 5) and peripheral blood samples (lanes 2 and 6). The arrow indicates large amplification products (> 1 kb) detected with e1a2 primers. Lane 3, positive control for e1a2 transcript (244 bp); lanes 4 and 7, blank controls; lane M, PCR markers (Promega). (b) Schematic representation and sequence of BCR-ABL junction in the mRNA of the patient. Solid lines indicate the splicing between BCR exon 8, neo-exon from BCR intron 8 and ABL exon 2, which occurred in the patient’s mRNA. Dotted lines indicate an expected splicing between BCR exon 8 and ABL exon 2. Below, the first line is the sequence of the 3′ end of BCR exon e8 and of the 5′ end of ABL exon 2, the second line is the sequence of the neo-exon from BCR intron 8 and the third line is the sequence of acceptor and donor splice sites surrounding this new exon. Canonical dinucleotides GT and AG at the 5′ and 3′ intron boundaries are given in bold. The scores for the splice sites calculated using the splice site detector program NetGene2 are indicated.
See this image and copyright information in PMC

References

    1. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, Branford S, Lim LC, Kegel T, Martinelli G, Hochhaus A, Druker BJ, Deininger MW. e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants? Leukemia. 2005;19:681–684. - PubMed
    1. Martiat P, Mecucci C, Nizet Y, Stul M, Philippe M, Cassiman JJ, Michaux JL, Van den Berghe H, Sokal G. P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma. Leukemia. 1990;4:751–754. - PubMed
    1. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood. 1998;92:2338–2344. - PubMed
    1. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318–2357. - PubMed
    1. Cortes J, Talpaz M, O’Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425–3432. - PubMed

MeSH terms